ALK is altered in 1.71% of mature B-cell non-hodgkin lymphoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BCL2 is altered in 21.15% of mature B-cell non-hodgkin lymphoma patients [2].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL2 status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BCL6 is altered in 5.85% of mature B-cell non-hodgkin lymphoma patients [2].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC is altered in 7.91% of mature B-cell non-hodgkin lymphoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYCN is altered in 0.78% of mature B-cell non-hodgkin lymphoma patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].